Table 1.

Baseline characteristics

Patients (N=20)	Number (%); Median [Range]
Age	61 [27–85]
Self-reported race/ethnicity: White	13 (65)
Male	10 (50)
Hemoglobin (g/dL)	12.8 [9.2–15.2]
β2-microglobulin (mg/L)	2.3 [0.8–6.2]
Lactate dehydrogenase (U/L)	222 [129–338]
Follicular lymphoma (FL) Marginal zone lymphoma (MZL) Mantle cell lymphoma Richter syndrome	15 (75) 3 (15) 1 (5) 1 (5)
Indolent B-NHL (FL and MZL)	18 (90)
FL Grade 3A	3/15 (20)
Bone marrow, involved	4 (20)
B-symptoms, present	3 (15)
Ann Arbor Stage III-IV	18 (90)
Involved nodal areas (n)	3 [1–5]
Largest lymph node (cm)	2.9 [1.5–5.6]
Extra-nodal disease, present	11 (55)
SUVmax	15.8 [3.9–53.7]
FLIPI score, low  Intermediate  high	3/15 (20) 3/15 (20) 9/15 (60)
FLIPI-2 score, low   Intermediate   high	4/15 (27) 7/15 (46) 4/15 (27)
PRIMA PI, low  Intermediate  high	11/15 (73) 3/15 (20) 1/15 (7)
Previous systemic therapies (n)	1 [1–3]
Previous anti-CD20 antibody	20 (100)
Previous chemotherapy	13 (72)
Previous POD24	16 (80)

SUV, standardized uptake volume; FLIPI, follicular lymphoma international prognostic index; PI, prognostic index; POD24, progression of disease within 24 months